An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

The purpose of this study is to determine which doses of Urelumab and Nivolumab are safe and tolerable when they are given together.

Principal Investigator

  • Shivaani Kummar, MD, FACP

Stanford Investigator(s)


Primary Contact:
Kristine McGlennen
(650) 723-3589